Targeted Drug Delivery Market, by Disease Type (Cardiovascular Diseases, Pulmonary Diseases, Infectious Diseases, Endocrine Diseases, and Oncological Disorders), by Application (First Order Targeting (Organ Compartmentalization), Second Order Targeting (Cellular Targeting), and Third Order Targeting (Intracellular Targeting), by End User (Hospitals, Clinics, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030
Targeted drug delivery is the selective transport of drug to targeted tissues, organs, and cells through various drug carriers. Targeted drug delivery is designed to improve the pharmacological and therapeutic properties of conventional drugs and to overcome problems, such as limited solubility, drug aggregation, poor bio-distribution, and lack of selectivity, control drug release carrier, and reduce normal tissue damage. With the non-toxic and biodegradable characteristics, it can increase the retention of drug in the lesion site and the permeability, and improve the concentration of the drug in lesion site.
There are different types of drug delivery vehicles, such as polymeric micelles, liposomes, lipoprotein-based drug carriers, nanoparticle drug carriers, and dendrimers. An ideal drug delivery vehicle is nontoxic, biocompatible, biodegradable, and non-immunogenic and must avoid recognition by the host defense mechanism.
Market Dynamics
The increasing population of diabetes, rising research and development activities, and increasing adoption of inorganic growth strategies such as mergers, acquisitions, partnerships, and collaborations by key players operating in the market are the major factors that are expected to drive the growth of the global targeted drug delivery market over the forecast period. For instance, in September 2021, Oncxerna Therapeutics Inc. a precision medicine company using an innovative RNA-expression based biomarker platform to predict patient responses to its targeted oncology therapies, has announced new clinical and biomarker data from its bavituximab program in an electronic poster at the European Society of Medical Oncology (ESMO) congress 2021.
Moreover, the increasing cases of diabetes are also anticipated to augment the market growth over the forecast period. According to the International Diabetes Federation in 2021, approximately 537 million adults (20-79) are living with diabetes.
Key features of the study:
This report provides an in-depth analysis of the global targeted drug delivery market, market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global targeted drug delivery market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study include AbbVie Inc., Ablynx NV by Sanofi SA, Arrowhead Pharmaceuticals, Inc., Baxter International Inc., AstraZeneca PLC, Boston Scientific Corporation, Becton, Depomed, Inc., Fraunhofer Gesellschaft Munchen, Janssen Global Services, LLC., Luye Pharma Group, Pfizer Inc., Quark Pharmaceuticals Inc., Rexahn Pharmaceuticals Inc., Savara Inc., Roche Holding AG, Suda Limited, Vectura Group PLC, Taiwan Liposome Company, Ltd., and 3M.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global targeted drug delivery market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global targeted drug delivery market
Detailed Segmentation:
Global Targeted Drug Delivery Market, By Disease Type:
Cardiovascular Diseases
Pulmonary Diseases
Infectious Diseases
Endocrine Diseases
Oncological Disorders
Global Targeted Drug Delivery Market, By Application:
First Order Targeting (Organ Compartmentalization)
Second Order Targeting (Cellular Targeting)
Third Order Targeting (Intracellular Targeting)
Global Targeted Drug Delivery Market, By End User:
Hospitals
Clinics
Others
Global Targeted Drug Delivery Market, By Region:
North America
By Disease Type
Cardiovascular Diseases
Pulmonary Diseases
Infectious Diseases
Endocrine Diseases
Oncological Disorders
By Application
First Order Targeting (Organ Compartmentalization)
Second Order Targeting (Cellular Targeting)
Third Order Targeting (Intracellular Targeting)
By End User
Hospitals
Clinics
Others
By Country
U.S.
Canada
Latin America
By Disease Type
Cardiovascular Diseases
Pulmonary Diseases
Infectious Diseases
Endocrine Diseases
Oncological Disorders
By Application
First Order Targeting (Organ Compartmentalization)
Second Order Targeting (Cellular Targeting)
Third Order Targeting (Intracellular Targeting)
By End User
Hospitals
Clinics
Others
By Country
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Disease Type
Cardiovascular Diseases
Pulmonary Diseases
Infectious Diseases
Endocrine Diseases
Oncological Disorders
By Application
First Order Targeting (Organ Compartmentalization)
Second Order Targeting (Cellular Targeting)
Third Order Targeting (Intracellular Targeting)
By End User
Hospitals
Clinics
Others
By Country
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
By Disease Type
Cardiovascular Diseases
Pulmonary Diseases
Infectious Diseases
Endocrine Diseases
Oncological Disorders
By Application
First Order Targeting (Organ Compartmentalization)
Second Order Targeting (Cellular Targeting)
Third Order Targeting (Intracellular Targeting)
By End User
Hospitals
Clinics
Others
By Country
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
By Disease Type
Cardiovascular Diseases
Pulmonary Diseases
Infectious Diseases
Endocrine Diseases
Oncological Disorders
By Application
First Order Targeting (Organ Compartmentalization)
Second Order Targeting (Cellular Targeting)
Third Order Targeting (Intracellular Targeting)
By End User
Hospitals
Clinics
Others
By Country
GCC
Israel
Rest of Middle East
Africa
By Disease Type
Cardiovascular Diseases
Pulmonary Diseases
Infectious Diseases
Endocrine Diseases
Oncological Disorders
By Application
First Order Targeting (Organ Compartmentalization)
Second Order Targeting (Cellular Targeting)
Third Order Targeting (Intracellular Targeting)
By End User
Hospitals
Clinics
Others
By Country
South Africa
Central Africa
North Africa
Company Profiles
AbbVie Inc.*
Company Overview
Material Portfolio
Financial Performance
Key Highlights
Market Strategies
Ablynx NV by Sanofi SA
Arrowhead Pharmaceuticals, Inc.
Baxter International Inc.
AstraZeneca PLC
Boston Scientific Corporation
Becton
Depomed, Inc.
Fraunhofer Gesellschaft Munchen
Janssen Global Services, LLC
Luye Pharma Group
Pfizer Inc.
Quark Pharmaceuticals Inc.
Rexahn Pharmaceuticals Inc.
Savara Inc.
Roche Holding AG
Suda Limited
Vectura Group PLC
Taiwan Liposome Company, Ltd.
3M
“*” marked represents similar segmentation in other categories in the respective section.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook